00:01In a major development that could transform both obesity treatment and cancer care,
00:07weight loss drugs like Ozempic and VigoV are showing remarkable potential to prevent and fight cancer.
00:19Millions of people worldwide already rely on GLP-1 receptor agonists,
00:26drugs such as semaglutide, inozempic, and VigoV to manage obesity and type 2 diabetes.
00:35Now, a series of studies presented at the world's largest oncology conference suggest
00:41these medications could play a powerful new role in preventing and treating cancer.
00:51The findings were unveiled at the American Society of Clinical Oncology's annual meeting in Chicago.
00:57One major analysis found that people taking these GLP-1 medications were 30% less likely
01:05to develop breast cancer, the world's most common cancer, compared to those not taking the drugs.
01:16A second study showed that adding these weight loss drugs to standard breast cancer treatment
01:22reduced the risk of patients dying from the disease by another 30%.
01:27Doctors say the benefits appear linked to significant weight loss, reduced inflammation,
01:34and possibly direct effects on cancer pathways.
01:41A third piece of research involving patients with breast, lung, bowel, or liver cancer found
01:48those on the weight loss drugs were up to 50% less likely to have their disease spread to stage
01:554.
01:56Reductions in metastatic progression ranged from 38% to 50% in key obesity-related cancers.
02:08These are largely real-world observational studies, which show strong associations but cannot yet prove
02:15direct cause and effect. Randomised clinical trials are still needed.
02:20However, experts are excited about the potential dual benefit for the millions battling obesity,
02:26a known driver of many cancers.
02:32While not a miracle cure, these findings add to growing evidence that controlling obesity
02:37with effective medications could be a powerful weapon against cancer.
02:42Always consult your doctor before starting any new treatment.
Comments